Needham Maintains Buy on Recursion Pharmaceuticals, Raises Price Target to $17
Needham Maintains Buy on Recursion Pharmaceuticals, Raises Price Target to $17
Needham維持對Recursion Pharmicals的買入，將目標股價上調至17美元
Needham analyst Gil Blum maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and raises the price target from $15 to $17.
Needham分析師吉爾·布魯姆維持Recursion Pharmicals（納斯達克股票代碼：RXRX）的買入並將目標股價從15美元上調至17美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。